Multicenter evaluation of a new immunoassay for procalcitonin measurement on the Kryptor® System

被引:73
作者
Steinbach, G
Rau, B
Debard, AL
Javourez, JF
Bienvenu, J
Ponzio, A
Bonfà, A
Hubl, W
Demant, T
Külpmann, WR
Buchholz, J
Schumann, G
机构
[1] Univ Ulm, Inst Klin Chem & Pathobiochem, D-89075 Ulm, Germany
[2] Univ Saarland, Dept Gen Visceral & Vasc Surg, Homburg, Germany
[3] Ctr Hosp Lyon Sud, Immunol Lab, F-69310 Pierre Benite, France
[4] Hosp Prato, Sect Endocrinol & Lab Anal, Prato, Italy
[5] Hosp Prato, Dept Anaesthesia Reanimat & Antalg Therapy, Prato, Italy
[6] Hosp Dresden Friedrichstadt, Inst Clin Chem & Lab Med, Dresden, Germany
[7] Hannover Med Sch, Hannover, Germany
关键词
automation; homogenous immunoassay; procalcitonin;
D O I
10.1515/CCLM.2004.077
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
We compared the manually performed LUMItest(R) procalcitonin (PCT) assay with the newly developed fully mechanized Kryptor(R) PCT assay and determined the essential assay characteristics of this assay. The new Kryptor(R) PCT assay was evaluated according to modified NCCLS EP-10/EP-6 protocols in five different laboratories. Samples from 696 patients were assayed using the original LUMItest(R) PCT assay and the new Kryptor(R) PCT assay. Possible interference by hemoglobin, triglycerides and bilirubin was evaluated by spiking patient plasma with the appropriate substances. The functional assay sensitivity (FAS) was determined by analyzing samples with low PCT concentrations. The FAS of the new Kryptor(R) PCT assay was 0.04 ng/ml and the imprecision within and betweenseries below 5% and below 10%, respectively. Within the smallest range of determination, from 0.3 ng/ml to 50 ng/ml, common to the LUMItest(R) PCT assay (x) and the Kryptor(R) PCT assay (y) the values correlated well: y=0.64+0.94x, s.(xy)=2.78 ng/ml. The performance characteristics of the Kryptor(R) PCT assay are fully compatible with the intended clinical use. The assay allows determination of PCT in a turnaround time (TAT) of about 20 minutes and thus is adequate for STAT analyses.
引用
收藏
页码:440 / 449
页数:10
相关论文
共 12 条
  • [1] HIGH SERUM PROCALCITONIN CONCENTRATIONS IN PATIENTS WITH SEPSIS AND INFECTION
    ASSICOT, M
    GENDREL, D
    CARSIN, H
    RAYMOND, J
    GUILBAUD, J
    BOHUON, C
    [J]. LANCET, 1993, 341 (8844) : 515 - 518
  • [2] BOHUON C, 1994, CLIN INT CARE S, V5, P88
  • [3] Evolution and significance of circulating procalcitonin levels compared with IL-6, TNF alpha and endotoxin levels early after thermal injury
    Carsin, H
    Assicot, M
    Feger, F
    Roy, O
    Pennacino, I
    LeBever, H
    Ainaud, P
    Bohuon, C
    [J]. BURNS, 1997, 23 (03) : 218 - 224
  • [4] Procalcitonin as a marker for the early diagnosis of neonatal infection
    Gendrel, D
    Assicot, M
    Raymond, J
    Moulin, F
    Francoual, C
    Badoual, J
    Bohuon, C
    [J]. JOURNAL OF PEDIATRICS, 1996, 128 (04) : 570 - 573
  • [5] HIGH SERUM PROCALCITONIN LEVEL IN A 4-YEAR-OLD LIVER-TRANSPLANT RECIPIENT WITH A DISSEMINATED CANDIDIASIS
    GERARD, Y
    HOBER, D
    PETITJEAN, S
    ASSICOT, M
    BOHUON, C
    MOUTON, Y
    WATTRE, P
    [J]. INFECTION, 1995, 23 (05) : 310 - 311
  • [6] Procalcitonin aids diagnosis of adrenocortical failure
    Hatherill, M
    Jones, G
    Lim, E
    Tibby, SM
    Murdoch, IA
    [J]. LANCET, 1997, 350 (9093) : 1749 - 1750
  • [7] Procalcitonin, soluble interleukin-2 receptor, and soluble E-selectin in predicting the severity of acute pancreatitis
    Kylänpää-Bäck, ML
    Takala, A
    Kemppainen, EA
    Puolakkainen, PA
    Leppäniemi, AK
    Karonen, SL
    Orpana, A
    Haapiainen, RK
    Repo, H
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (01) : 63 - 69
  • [8] Procalcitonin as a specific marker of bacterial infection in adults
    Monneret, G
    Doche, C
    Durand, DV
    Lepape, A
    Bienvenu, J
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 1998, 36 (01) : 67 - 68
  • [9] The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis
    Rau, B
    Steinbach, G
    Gansauge, F
    Mayer, JM
    Grünert, A
    Beger, HG
    [J]. GUT, 1997, 41 (06) : 832 - 840
  • [10] RICHARDLENOBLE D, 1997, T ROY SOC TROP MED H, V91, P306